journal article·2025-02Open access

Palmitic Acid Accelerates Endothelial Cell Injury and Cardiovascular Dysfunction via Palmitoylation of PKM2

Yu He, Senlin Li, Lujing Jiang, Kejue Wu, Shanshan Chen, Linjie Su, Cui Liu, Peiqing Liu, Wenwei Luo, Shilong Zhong, Zhuoming Li

Advanced Science· Volume 12· Issue 5

Abstract

Abstract High serum level of palmitic acid(PA) is implicated in pathogenesis of cardiovascular diseases. PA serves as the substrate for protein palmitoylation. However, it is still unknown whether palmitoylation is involved in PA‐induced cardiovascular dysfunction. Here, in clinical cohort studies of 1040 patients with coronary heart disease, high level of PA is associated with risk of major adverse cardiovascular events (MACE) and death. In ApoE−/−mice, 10 mg/kg−1 PA treatment induces blood pressure elevation, cardiac contractile dysfunction, endothelial dysfunction and atherosclerotic plaqueformation. In endothelial cells, inhibition of palmitoylation bypalmitoyl‐transferase inhibitor 2‐BP eliminates PA‐induced endothelial injury, whereas promotion of palmitoylation by depalmitoylase inhibitor ML349 exacerbates the harmful effect of PA. Palmitoyl‐proteomics analysis identifies pyruvate kinase isozyme type M2 (PKM2) as the palmitoylated protein responsible for PA‐induced endothelial injury, and Cys31 as the predominant palmitoylated site. PKM2‐C31S mutants (cysteine replaced by serine) prevents PA‐induced endothelial injury. Endothelial‐specific AAV‐C31S PKM2endo ameliorates cardiovascular dysfunction caused by PA in ApoE−/− mice. Mechanistically, PKM2‐C31 palmitoylation impairs PKM2 tetramerization to inhibit its pyruvate kinase activity and endothelial glycolysis. Finally, zDHHC13 is identified as the palmitoyl acyltransferase of PKM2. In conclusion, these findings suggest that PKM2‐C31 palmitoylation contributes to PA‐induced endothelial injury and cardiovascular dysfunction.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer, Lipids, and Metabolism · Diabetes, Cardiovascular Risks, and Lipoproteins · Advanced Glycation End Products research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmacology and Toxicology School of Pharmaceutical Sciences National and Local United Engineering Lab of Druggability and New Drugs Evaluation Guangdong Engineering Laboratory of Druggability and New Drug Evaluation Guangdong Provincial Key Laboratory of New Drug Design and Evaluation Sun Yat‐sen University Guangzhou 510006 P. R. China

Department of Pharmacy Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences) Southern Medical University Guangzhou 510080 P. R. China

Guangdong Provincial Key Laboratory of Coronary Heart Disease Prevention Guangdong Cardiovascular Institute Guangdong Provincial People's Hospital Guangdong Academy of Medical Sciences Guangzhou 510080 P. R. China

School of Medicine South China University of Technology Guangzhou 510006 P. R. China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Guangxi Province · Guangdong Provincial Key Laboratory of Construction Foundation

References (59)

Show source-provided references
1. 10.15252/embr.20174433110.15252/embr.201744331 ↗
2. 10.1016/j.chembiol.2018.05.00310.1016/j.chembiol.2018.05.003 ↗
3. 10.1016/j.dsx.2019.03.03310.1016/j.dsx.2019.03.033 ↗
4. 10.3390/nu1308259010.3390/nu13082590 ↗
5. 10.3389/fphys.2017.0090210.3389/fphys.2017.00902 ↗
6. 10.1253/circj.CJ-18-024010.1253/circj.CJ-18-0240 ↗
7. 10.1161/JAHA.119.01288110.1161/JAHA.119.012881 ↗
8. 10.1161/STROKEAHA.118.02213210.1161/STROKEAHA.118.022132 ↗
9. 10.1016/j.clnu.2013.03.00110.1016/j.clnu.2013.03.001 ↗
10. 10.1038/nrm208410.1038/nrm2084 ↗
11. 10.1080/10409238.2017.140919110.1080/10409238.2017.1409191 ↗
12. 10.1016/j.jhep.2018.04.00610.1016/j.jhep.2018.04.006 ↗
13. 10.1038/s41589-019-0344-010.1038/s41589-019-0344-0 ↗
14. 10.1161/01.CIR.103.13.181310.1161/01.CIR.103.13.1813 ↗
15. 10.1016/j.chemphyslip.2007.08.00210.1016/j.chemphyslip.2007.08.002 ↗
16. 10.1053/meta.2002.3520210.1053/meta.2002.35202 ↗
17. 10.3389/fendo.2022.86063410.3389/fendo.2022.860634 ↗
18. 10.1161/CIRCRESAHA.120.31593710.1161/CIRCRESAHA.120.315937 ↗
19. 10.1124/pharmrev.120.00009610.1124/pharmrev.120.000096 ↗
20. 10.1172/JCI12091210.1172/JCI120912 ↗
21. 10.1152/ajpcell.1997.273.1.C20510.1152/ajpcell.1997.273.1.C205 ↗
22. 10.1002/pro.50510.1002/pro.505 ↗
23. 10.1016/j.cell.2012.07.01810.1016/j.cell.2012.07.018 ↗
24. 10.1038/ncomms1282310.1038/ncomms12823 ↗
25. 10.1016/S0140-6736(23)00215-510.1016/S0140-6736(23)00215-5 ↗
26. 10.1038/s41467-024-45582-810.1038/s41467-024-45582-8 ↗
27. 10.1161/CIRCRESAHA.115.30630110.1161/CIRCRESAHA.115.306301 ↗
28. 10.1161/ATVBAHA.117.30901710.1161/ATVBAHA.117.309017 ↗
29. 10.3390/ijms15112087610.3390/ijms151120876 ↗
30. 10.1007/s00424-017-1979-x10.1007/s00424-017-1979-x ↗
31. 10.1016/j.redox.2022.10238010.1016/j.redox.2022.102380 ↗
32. 10.1093/cvr/cvaa14910.1093/cvr/cvaa149 ↗
33. 10.1161/ATVBAHA.113.30284810.1161/ATVBAHA.113.302848 ↗
34. 10.1074/jbc.M00187020010.1074/jbc.M001870200 ↗
35. 10.1016/j.cell.2013.06.03710.1016/j.cell.2013.06.037 ↗
36. 10.1161/ATVBAHA.113.30304110.1161/ATVBAHA.113.303041 ↗
37. 10.1016/j.cmet.2013.11.00810.1016/j.cmet.2013.11.008 ↗
38. 10.1096/fj.202001634R10.1096/fj.202001634R ↗
39. 10.3390/antiox1211195610.3390/antiox12111956 ↗
40. 10.1161/CIRCRESAHA.119.31620610.1161/CIRCRESAHA.119.316206 ↗
41. 10.1038/s41467-018-07132-x10.1038/s41467-018-07132-x ↗
42. 10.1016/j.semcancer.2005.04.00910.1016/j.semcancer.2005.04.009 ↗
43. 10.1007/s13238-015-0132-x10.1007/s13238-015-0132-x ↗
44. 10.1158/0008-5472.CAN-17-272610.1158/0008-5472.CAN-17-2726 ↗
45. 10.1038/ncb363010.1038/ncb3630 ↗
46. 10.1073/pnas.170414511510.1073/pnas.1704145115 ↗
47. 10.1038/s41467-017-02655-110.1038/s41467-017-02655-1 ↗
48. 10.1186/s12964-019-0405-810.1186/s12964-019-0405-8 ↗
49. 10.1038/s41586-020-2799-210.1038/s41586-020-2799-2 ↗
50. 10.1186/s13578-022-00863-x10.1186/s13578-022-00863-x ↗
51. 10.1371/journal.pone.015701210.1371/journal.pone.0157012 ↗
52. 10.1111/febs.1677210.1111/febs.16772 ↗
53. 10.1038/s41419-022-05109-910.1038/s41419-022-05109-9 ↗
54. 10.1093/abbs/gmy14710.1093/abbs/gmy147 ↗
55. 10.1016/j.abb.2022.10932110.1016/j.abb.2022.109321 ↗
56. 10.1093/cvr/cvac02610.1093/cvr/cvac026 ↗
57. 10.1111/bph.1582610.1111/bph.15826 ↗
58. 10.1038/ncomms1569910.1038/ncomms15699 ↗
59. 10.1167/iovs.14-1472210.1167/iovs.14-14722 ↗